Trinity biotech announces launch of fda-cleared preeclampsia testing service

Fda-cleared preclara™ ratio (sflt-1/plgf) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes dublin, aug. 07, 2025 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of a new testing service for preeclampsia, a significant advancement in maternal health diagnostics. the service is planned to be rolled out in q3 2025 through trinity biotech's new york-based reference laboratory.
TRIB Ratings Summary
TRIB Quant Ranking